Study Shows Fat Reduction Laser Reduces Hunger and LDL Levels
May 5, 2009- McKinney, TX

Erchonia Medical, global leader in low level laser healthcare applications, announces today that its newest laser for body sculpting, Zerona, has been clinically shown to reduce the levels of the hunger-hormone leptin, and lipoprotein (LDL). A 22 participant pilot study revealed that Zerona not only reduced circumferential inches following a two week treatment phase, but also lowered all patients’ leptin levels and reduced low density lipoprotein numbers in over 50% of the participants in just 2 weeks.

Although Zerona is already positioned ahead of its competitors in terms of its ability to non-invasively, safely and effectively reduce an average of 3.64 inches around the waist, hips and thighs, this new data could have beneficial results for many patients struggling with overeating. Suppressing the very hormones that may cause individuals to be overweight or obese can further aid Zerona patients with their weight-loss goals.

Erchonia President, Steve Shanks, comments, “For most devices, the patient comes in , receives the treatment and leaves; the reason why that person was overweight or obese to begin with is not addressed. By suppressing the hunger-hormone leptin, patients’ appetites can be lessened helping them modify their diets and establish portion control going forward.”

In addition to reducing inches, suppressing hunger and reducing LDL levels, Zerona is also unique because it does not destroy fat tissue, unlike the majority of other devices on the market. Zerona promotes a biological cascade within the cell provoking the formation of tiny pores within the protective barrier of the cell. Then, stored fatty material leaves the cell, causing it to collapse safely.

For more information on the Zerona laser, visit www.myzerona.com.

Pilot Studies Explore Low Level Laser’s Effect on LDL, Leptin, and Parkinson’s Disease
April 12, 2010- McKinney, TX

Erchonia Medical presents three new studies at the upcoming American Society of Laser Medicine and Surgery Annual Conference this week in Phoenix, AZ.

Study 1
Erchonia will be presenting a study it conducted using low level lasers to treat late stage Parkinson’s disease. Eight volunteers between 18 and 80 years old with late stage PD participated in the non-controlled, non-randomized study and received low level laser treatments daily for two weeks. Patients were asked to rate the severity of their symptoms (balance, gait, freezing, cognitive function, rolling in

bed, and speech difficulties) from 0-10 using the Visual Analog Scale. All participants demonstrated a decrease in VAS from baseline to study endpoint.

Study 2
The second study Erchonia plans to present shows how low-level lasers may reduce low density lipoprotein levels (LDL). Forty one patients between 18 and 65 participated in Erchonia’s non-controlled, non-randomized study. Participants received a 40-minute Zerona laser treatment three times a week for two weeks and demonstrated a reduction in low-density lipoprotein levels of 12.05 points, a 13% reduction. This study suggests that low level laser therapy may serve as a non-invasive way to reduce LDL levels in two weeks.

Study 3
Erchonia’s third study explores how its Zerona laser impacts leptin levels, the hormone linked to hunger. Twenty volunteers between the ages of 18 and 65 participated in Erchonia’s non-controlled, non-randomized study. Participants received 40-minute Zerona low-level laser treatments three times per week for two weeks. All participants demonstrated a reduction in leptin levels compared to their baseline – on average, a 50% decrease. Since leptin levels are associated with hunger, this study shows low level laser technology may noninvasively suppress the appetite. 

Ryan Maloney, Erchonia’s medical director and one of the authors of the studies comments, “Although these were non-controlled, non-randomized pilot studies, they each showed promising new applications for low level laser technology. Further study is needed, but Erchonia is paving the way for new noninvasive healthcare technologies with a commitment to research and innovation.”